(Q38959765)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

S Cheng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

A Guo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

P Lu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

J Ma

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

M Coleman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

5 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

895-900

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2014.263

16 February 2020

exact match

0 references

cites work

Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.

1 reference

12 December 2020

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

1 reference

12 December 2020

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

1 reference

12 December 2020

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

1 reference

12 December 2020

New insights into pre-BCR and BCR signalling with relevance to B cell malignancies

1 reference

12 December 2020

Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis

1 reference

12 December 2020

B cell antigen receptor signaling 101.

1 reference

12 December 2020

CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells

1 reference

12 December 2020

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

12 December 2020

Early events in B cell activation

1 reference

12 December 2020

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

1 reference

12 December 2020

Ibrutinib resistance in chronic lymphocytic leukemia

1 reference

12 December 2020

B cell signaling and fate decision.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities

1 reference

12 December 2020

Metabolism and disposition of dasatinib after oral administration to humans

1 reference

12 December 2020

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

1 reference

12 December 2020

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

1 reference

12 December 2020

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

12 December 2020

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

12 December 2020

Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma.

1 reference

12 December 2020

SYK inhibition and response prediction in diffuse large B-cell lymphoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

16 February 2020

1002833948

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25189416%20AND%20SRC:MED&resulttype=core&format=json